Adopting a healthy lifestyle could substantially reduce premature mortality and prolong life expectancy in US adults. The BMJ study states, “adherence to a healthy lifestyle at mid-life is associated with a longer life expectancy free of major chronic diseases.” That message is missing in patient communication with HCPs.
Month: April 2023
The “times are changing,” but has the FDA remained in the past? Aduhelm, the failed Bioigen drug, should never have been approved, and the FDA’s guidance on DTC needs to be revised. The FDA needs new leadership and a visionary to lead the agency.
Mounjaro, already on the market to treat Type 2 diabetes in the U.S., is going head to head with Novo’s drug. The stakes are enormous in need, expected to be over $30 billion by 2030, according to analysts at Cowen Inc. Novo Nordisk was projected to capture the largest share, with Wegovy sales topping $7 billion, but if Lilly’s head-to-head trials turn out well Mounjaro, and Lilly, could be huge winners.
While the media and Congress like to focus on the cost of healthcare here in the U.S., the real issue is the failure to treat patients as people rather than address their health conditions. Every patient is different, and what they hear from their doctor varies. Can our healthcare system really treat patients as individuals?
Oncologists are experts in evaluating the nature of cancer, how it’s treated, and the side effects of the treatments used. As cancer treatments continue to improve, oncologists constantly assess their patients’ best options but do patients always listen?
Horizon’s CEO, Tim Walbert, will reportedly get around $135 million when the company is sold to Amgen. He has mastered a particular kind of industry expertise: taking drugs invented and tested by other people, wrapping them expertly in hard-nosed marketing and warm-hued patient relations, raising their prices, and enjoying astounding revenues without spending one dime on drug development.
Patients hear misinformation on new weight loss drugs from social media influencers, but they often aren’t getting ALL the information they should know. Regulatory systems are most interested in pharma’s claims, not necessarily those of doctors or their enthused patients. Should the FDA do something?
Cancer death rates continued to decline among men, women, children, adolescents, and young adults in every significant racial and ethnic group in the United States from 2015 to 2019, according to the latest Annual Report to the Nation on the Status of Cancer. At a time when expensive new cancer treatments are increasing rapidly, patients have more therapy choices than ever before. Yet patients are kept mainly in the dark because their doctors either can’t or won’t communicate clearly.